Announcement • Jul 06
Molecular Partners Provides Update on Clinical Progress Across Pipeline of Darpin Radiotherapeutics Molecular Partners has made significant progress in the first months of 2026, with its DLL3 radiotherapy candidate MP0712 progressing through Phase 1 initiation and dosing of patients in the first cohort. Dosing of patients is ongoing in the first cohort of the US multicenter Phase 1/2a study of MP0712 (ClinicalTrials.gov: NCT07278479). MP0712, targeting the tumor-associated protein delta-like ligand 3 (DLL3) and carrying the therapeutic payload Lead-212 (212Pb), is being developed for patients with small cell lung cancer and other neuroendocrine cancers, with strategic partner Orano Med. The Phase 1 study contains up to 4 dose levels (cohorts). Each patient will receive up to 4 doses of MP0712 within their assigned dose level. At present five centers are open and recruiting. Initial data from the MP0712 Phase 1/2a study are expected within the next months, with a more comprehensive dataset on safety and efficacy in 2027. Additional compassionate care work has been initiated by the Nuclear Medicine Research Institute in South Africa utilizing 225Ac-loaded DLL3 Radio-DARPin, highlighting the versatility of DARPins as isotope agnostic vectors. Dr. Mike Sathekge of the Nuclear Medicine Research Institute (NuMeRI) in South Africa has made a request for an early-access clinical program (under the legal framework for compassionate care in South Africa, Section 21 of the Medicines and Related Substances Act) with a DLL3-targeting Radio-DARPin, this time utilizing 177Lu/225Ac as theranostics pair to image and treat patients, respectively (referred to as MP0714). PanTera, a radioisotope producer, is among the suppliers of 225Ac for the use of MP0714 at NuMeRI. The Company’s ability to explore targets in an alpha isotope-agnostic manner is supported by preclinical data presented at the 3rd Global Radiopharmaceuticals Development Summit in March 2026 in Shanghai, China. The data show highly comparable biodistribution profiles of two Radio-DARPin candidates, each specific for a different tumor target, labeled with 177Lu or 203Pb. Imaging with 177Lu can be indicative of behavior with the therapeutic isotope 225Ac, and similarly with 203Pb for 212Pb. MP0726, the Company’s second Radio-DARPin candidate, targets mesothelin (MSLN), a tumor target overexpressed across several cancers with high unmet need such as ovarian cancer. Molecular Partners plans to advance MP0726 towards first-in-human imaging in H2 2026. As part of its growing pipeline, the Company plans two INDs across its portfolio of targeted cancer therapeutics in 2027 and expects to nominate a new RDT target in the second half of this year. Molecular Partners develops targeted alpha therapeutics leveraging its Radio-DARPins as isotope-agnostic vectors with the potential to unlock a broad range of cancer targets and indications. Molecular Partners designs its Radio-DARPin candidates matching disease and target biology with vector and isotope properties to address unmet medical needs. Building on the DARPins’ unique properties, Molecular Partners has developed a proprietary Radio-DARPin platform for precise delivery of potent radioactive payloads to tumor lesions. Molecular Partners’ Radio-DARPins address historic limitations of radioligand therapy, such as kidney accumulation and suboptimal tumor uptake, through optimized half-life extension and surface engineering approaches, while preserving the advantages of the small protein format. Molecular Partners has established partnerships with industry leaders covering the full value chain for the development of its Radio-DARPin therapeutics, including a strategic collaboration with Orano Med – pioneer in the development of 212Pb-based targeted alpha therapies (TAT), a non-exclusive development agreement with Eckert & Ziegler – global leader in radiopharmaceutical manufacturing, and a supply agreement with PanTera – a radioisotope producer. MOLN
Live News • Jul 06
Molecular Partners Advances DARPin Radiotherapeutics With Key Trials and First Data Approaching Molecular Partners reported progress across its DARPin radiotherapeutics pipeline, with DLL3-targeted MP0712 continuing in Phase 1/2a dosing, initial data expected in the coming months, mesothelin-targeted MP0726 planned for first-in-human imaging in the second half of 2026, and two IND filings plus a new target nomination scheduled around 2026 to 2027.
These timelines outline a sequence of clinical and regulatory events that could influence Molecular Partners’ development spend, partnership discussions and overall pipeline visibility over the next 12 to 24 months.
The stock last traded at CHF3.18, with the share price down 6.2% year to date, suggesting the market has yet to place a high value on these future clinical readouts.
The clear calendar of trials, imaging studies and INDs means upcoming data and regulatory updates may be the main drivers of sentiment around Molecular Partners, while delays or weaker-than-expected data remain key risks. Announcement • Jul 02
Molecular Partners And Orano Med Dose First Patients In Phase 1/2a Trial Of DLL3 Radio-DARPin MP0712 Molecular Partners and Orano Med announced that the first patients were dosed in the ongoing US multicenter Phase 1/2a study of drug candidate MP0712. MP0712, targeting the tumor-associated protein delta-like ligand 3 (DLL3) and carrying the therapeutic payload 212Pb, is the lead Radio-DARPin candidate being developed under a strategic partnership between Molecular Partners and Orano Med. DLL3 is a highly relevant target for radiopharmaceutical therapy due to its abundant expression in tumors of patients with small cell lung cancer (DLL3 is present in over 85% of SCLC tumors) and multiple other aggressive neuroendocrine tumors, while expression in healthy tissues is low. The program employs a “matched-pair” approach, in which a diagnostic imaging agent and a therapeutic agent share the same targeting molecule, allowing for accurate prediction of tumor uptake prior to treatment. Following an imaging and dosimetry step with 203Pb-labeled MP0712, patients in the Phase 1/2a study receive up to four doses of 212Pb-labeled MP0712 within their assigned dose level cohort. Dosing of patients is ongoing in cohort 1, with patients moving to repeat dosing. The study contains up to four dose levels. At present, five centers are open and actively recruiting in the US, with additional sites planned to open this year. Initial data from the MP0712 Phase 1/2a study are expected in the upcoming months, with a more comprehensive dataset on safety and efficacy in 2027. Molecular Partners develops targeted alpha therapeutics leveraging its Radio-DARPins as isotope-agnostic vectors with the potential to unlock a broad range of cancer targets and indications. Molecular Partners designs its Radio-DARPin candidates matching disease and target biology with vector and isotope properties to address unmet medical needs. Building on the DARPins’ unique properties, Molecular Partners has developed a proprietary Radio-DARPin platform for precise delivery of potent radioactive payloads to tumor lesions. Molecular Partners’ Radio-DARPins address historic limitations of radioligand therapy, such as kidney accumulation and suboptimal tumor uptake, through optimized half-life extension and surface engineering approaches, while preserving the advantages of the small protein format. DARPin (Designed Ankyrin Repeat Protein) therapeutics are a novel class of protein drugs based on natural binding proteins, which have been clinically-validated across several therapeutic areas and developed through to the registrational stage. The key properties of DARPins – intrinsic potential for high affinity and specificity, as well as small size, flexible architecture, and high stability – offer unmatched advantages to drug design, such as multispecificity, broad target range, and tunable half-life. Targeted alpha therapy (TAT) relies on a simple concept: combining the ability of biological molecules to target cancer cells with the short-range cell-killing capabilities of alpha-emitting radioisotopes. Alpha decay consists of the emission of a helium nucleus (alpha particle) together with very high linear energy transfer and a range emission of only few cell layers, resulting in irreparable double strand DNA breaks in cells adjacent only to area of alpha emission. This approach results in an increased cytotoxic potential toward cancer cells while limiting toxicity to nearby healthy cells. As a result, alpha emitters are considered as the most powerful payloads to be found for targeted therapies. 
